Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: A step towards diagnosis of prostate cancer

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 17-22

  Kumar, Vijay ^a   Hassan, Md Imtaiyaz ^a,b   Singh, Abhay Kumar ^a   Dey, Sharmistha ^a   Singh, Tej P ^a   Yadav, Savita ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Biomarker and tumor proliferation; Peptidic inhibitors; Prostrate specific antigen; Proteomics; Surface plasmon resonance

Indexed keywords

ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SYNTHETIC PEPTIDE;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; HYDROPHOBICITY; HYPERPLASIA; ISOENZYMES; KINETICS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY; SURFACE PLASMON RESONANCE;

EID: 67349156113     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.11.020     Document Type: Article

References (41)

1. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
2. Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145 (1991) 907-923
3. Lundwall A., and Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214 (1987) 317-322
4. Diamandis E.P. Prostate-specific antigen or human kallikrein 3? Recent developments. Tumour Biol 19 (1998) 65-67 discussion 67-68
5. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76 (1985) 1899-1903
6. Diamandis E.P., and Yousef G.M. Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 1 (2001) 182-190
7. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
8. Zhang W.M., Leinonen J., Kalkkinen N., Dowell B., and Stenman U.H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 41 (1995) 1567-1573
9. Okada T., Sato Y., Kobayashi N., et al. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim Biophys Acta 1525 (2001) 149-160
10. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293-306
11. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
12. Mikolajczyk S.D., Millar L.S., Marker K.M., et al. Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 45 (2000) 271-276
13. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181-2185
14. Jung K., Reiche J., Boehme A., et al. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. Clin Chem 50 (2004) 2292-2301
15. Charrier J.P., Tournel C., Michel S., et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 22 (2001) 1861-1866
16. Hassan M.I., Kumar V., Kashav T., Alam N., Singh T.P., and Yadav S. Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation. J Sep Sci 30 (2007) 1979-1988
17. Wu P., Leinonen J., Koivunen E., Lankinen H., and Stenman U.H. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 267 (2000) 6212-6220
18. Wu P., Zhu L., Stenman U.H., and Leinonen J. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin Chem 50 (2004) 125-129
19. Wu P., Stenman U.H., Pakkala M., Narvanen A., and Leinonen J. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 58 (2004) 345-353
20. Kozue S., Jun-ichi K., Kazuyuk H., Inhibitors against prostate-specific antigen. Patent No. 2001;6284734:http://www.wikipatents.com/6284734.html.
21. Hassan M.I., Kumar V., Singh T.P., and Yadav S. Structural model of human PSA: a target for prostate cancer therapy. Chem Biol Drug Des 70 (2007) 261-267
22. Hassan M.I., Kumar V., Somvanshi R.K., Dey S., Singh T.P., and Yadav S. Structure-guided design of peptidic ligand for human prostate specific antigen. J Pept Sci 13 (2007) 849-855
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
24. Chandra V., Jasti J., Kaur P., et al. Crystal structure of a complex formed between a snake venom phospholipase A(2) and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 A resolution. J Biol Chem 277 (2002) 41079-41085
25. Balk S.P., Ko Y.J., and Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 21 (2003) 383-391
26. Christensson A., Laurell C.B., and Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194 (1990) 755-763
27. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756-759
28. Nurmikko P., Pettersson K., Piironen T., Hugosson J., and Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47 (2001) 1415-1423
29. Kawinski E., Levine E., and Chadha K. Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate 50 (2002) 145-153
30. Schaller J., Akiyama K., Tsuda R., Hara M., Marti T., and Rickli E.E. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 170 (1987) 111-120
31. Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. Purification of a human prostate specific antigen. Invest Urol 17 (1979) 159-163
32. Isono T., Tanaka T., Kageyama S., and Yoshiki T. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 48 (2002) 2187-2194
33. Tabares G., Jung K., Reiche J., et al. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem 40 (2007) 343-350
34. Margosiak S.A., Vanderpool D.L., Sisson W., Pinko C., and Kan C.C. Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Biochemistry 35 (1996) 5300-5307
35. Khare S.D., and Dokholyan N.V. Molecular mechanisms of polypeptide aggregation in human diseases. Curr Protein Pept Sci 8 (2007) 573-579
36. Leinonen J., Wu P., Koivunen E., Narvanen A., and Stenman U.H. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen. Scand J Clin Lab Invest Suppl 233 (2000) 59-64
37. Nagasaki H., Watanabe M., Komatsu N., et al. Epitope analysis of a prostate-specific antigen (PSA) C-terminal-specific monoclonal antibody and new aspects for the discrepancy between equimolar and skewed PSA assays. Clin Chem 45 (1999) 486-496
38. Debela M., Magdolen V., Schechter N., et al. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem 281 (2006) 25678-25688
39. Robert M., Gibbs B.F., Jacobson E., and Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36 (1997) 3811-3819
40. Lovgren J., Airas K., and Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem 262 (1999) 781-789
41. Carvalho A.L., Sanz L., Barettino D., Romero A., Calvete J.J., and Romao M.J. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. J Mol Biol 322 (2002) 325-337